Ecofibre Limited (EOFBF) Fair Value & Analysis
Healthcare · US · Market cap $379K
Ecofibre Limited
EOFBF · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.3300 to $0.0010 (−99.7%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0010 – $0.0010 · fair‑value band $0.0010 – $0.0010 · the $0.0010 price screens above the $0.0010 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ecofibre Limited (EOFBF) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0010 — implying the stock looks roughly 0.1% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Ecofibre Limited generated revenue of $28.4M at a net margin of -58.2%. Revenue grew 3.2% year over year. It earns a return on equity of -57.7%. Net debt stands at $18.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Ecofibre Limited, together with its subsidiaries, engages in the polymer, health care, and hemp seed genetics businesses in the United States and Australia. The company operates through Ecofibre Advanced Technologies, Ananda Health, Ecofibre Genetics, and EOF Bio segments. It offers cannabinoid based health products for human and pet consumption. In addition, the company provides yarn, polymer textiles, and hemp related food products. Further, it is involved in patient-centered cannabinoid-based drug activities. Ecofibre Limited was incorporated in 2009 and is based in Sydney, Australia.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Ecofibre Limited reported revenue of $28.0M in FY2024 versus $50.7M in FY2020, a compound −13.8%/yr. Reported net income was −$44.3M in FY2024.
Is EOFBF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ecofibre Limited (EOFBF) undervalued?
What is the fair value of EOFBF?
What is the quality score of EOFBF?
What is the revenue of Ecofibre Limited (EOFBF)?
What is the net profit margin of EOFBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.